Insys Therapeutics enrolls first patient in phase II study for infantile spasms
Insys Therapeutics announced the Company has enrolled the first patient in a Phase II clinical study for the treatment of infantile spasms using its pharmaceutical CBD product candidate. In August 2015, the FDA granted orphan drug designation to Insys for its CBD candidate for treatment of IS. February 09, 2016